Add this result to my export selection Update to information on psychiatric disorders for chloroquine and hydroxychloroquine Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 27 November 2020 EMA’s safety committee (PRAC) has recommended updating product information for all chloroquine or hydroxychloroquine-containing medicines following a review that confirmed a link between the use of... Read Summary Type: Medicines Current Awareness (Remove filter) Type: Safety Alerts (Add filter)
Add this result to my export selection Ulipristal acetate for uterine fibroids: EMA recommends restricting use Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 16 November 2020 CHMP endorsed PRAC’s assessment of risk of liver injury but considered benefits of ulipristal in controlling fibroids may outweigh risk. It therefore recommends ulipristal remains available to treat... Read Summary Type: Medicines Current Awareness (Remove filter) Type: Safety Alerts (Add filter)
Add this result to my export selection Nitrosamines: EMA aligns recommendations for sartans with those for other medicines Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 13 November 2020 The main change concerns the limits for nitrosamines, which will now apply to the finished products (e.g. tablets). These limits, should ensure that excess risk of cancer from nitrosamines in any... Read Summary Type: Medicines Current Awareness (Remove filter) Type: Safety Alerts (Add filter)
Add this result to my export selection The Prescribing Observatory for Mental Health Topic 10 audit report Source: Royal College of Psychiatrists - RCPsych (Remove filter) Published by Royal College of Psychiatrists, 01 January 2016 An audit-based quality improvement programme to help mental health services improve prescribing of antipsychotics for children and adolescents. It is open to all secondary mental health services in... Read Summary Type: Implementation Support (Add filter) Type: Quality Indicators (Remove filter)
Add this result to my export selection European CHMP recommends approval of licence extension of avelumab (Bavencio) Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 11 December 2020 The licence extension as monotherapy, is for first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma who are progression-free following... Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection European CHMP recommends approval of tucatinib (Tukysa) for treatment of HER2-positive locally advanced or metastatic breast cancer Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 11 December 2020 Tucatinib is an oral antineoplastic protein kinase inhibitor of HER2 kinase. Its benefits include increased progression free survival and overall survival including in patients with metastases. Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection European CHMP recommends approval of potassium citrate / potassium hydrogen carbonate (Sibnayal) for treatment of distal renal tubular acidosis Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 11 December 2020 Available as prolonged-release granules, Sibnayal is an alkalising agent and buffer in metabolic acidosis. It is reported to correct metabolic acidosis in patients with distal renal tubular acidosis. Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection European CHMP recommends approval of fostemsavir (Rukobia) for treatment of multidrug resistant HIV-1 infection Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 11 December 2020 Fostemsavir is an oral antiviral that selectively inhibits the interaction between HIV and cellular CD4 receptors, thereby preventing viral entry into the host cells. Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection European CHMP recommends approval of selpercatinib (Retsevmo) for treatment of RET-fusion positive non-small cell lung cancer, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 11 December 2020 Selpercatinib is a RET receptor tyrosine kinase inhibitor, inhibiting wild-type RET receptor tyrosine kinase and multiple mutated isoforms. Reported benefits include objective response rate and... Read Summary Type: Medicines Current Awareness (Remove filter)
Add this result to my export selection European CHMP recommends approval of moxetumomab pasudotox (Lumoxiti) for treatment of relapsed or refractory hairy cell leukaemia Source: European Medicines Agency - EMA (Remove filter) Published by European Medicines Agency, 11 December 2020 Moxetumomab pasudotox is a CD22-targeted immunotoxin designed to direct the cytotoxic action of the truncated Pseudomonas exotoxin to cells which express the CD22 receptor. Reported benefits includes... Read Summary Type: Medicines Current Awareness (Remove filter)